<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591994</url>
  </required_header>
  <id_info>
    <org_study_id>OTOSUL 01/2007</org_study_id>
    <secondary_id>FMV 01/2006</secondary_id>
    <nct_id>NCT00591994</nct_id>
  </id_info>
  <brief_title>Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography</brief_title>
  <acronym>piribedil</acronym>
  <official_title>Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina de Valenca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina de Valenca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tinnitus is defined as the perception of sound in the absence of a external source. About 15
      % of the population is believed to experience tinnitus and for about 20 % of them it may
      become a very serious problem. Total comprehension of tinnitus pathophysiology has not yet
      been achieved, but modern theories focus in brain hyperactivity following inner ear damage,
      with involvement of various neurotransmitters. Piribedil,a dopamin agonist, has been used to
      treat tinnitus, focusing in dopamine release, which is inhibitory. Electrophysiological
      methods,like acoustic otoemissions and electrocochleography may reveal the changes in
      peripherical and central auditory pathways and help to choose the specific patients who could
      benefit from piribedil treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>THI - Tinnitus Handicap Inventory</measure>
    <time_frame>Months 3 and 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS - Visual Analog Scale</measure>
    <time_frame>Months 3 and 6</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Tinnitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piribedil</intervention_name>
    <description>50 mg once a day, after lunch 3 month therapy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  tinnitus for more than 6 months

          -  THI &gt; 38

          -  no central acting drugs in the last 6 months

          -  tympanogram type A-n

        Exclusion Criteria:

          -  vascular and muscular tinnitus

          -  concomitant TMJ disorders

          -  abnormal otoscopy

          -  mixed and conductive hearing losses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo R Figueiredo, M.D.,M.Sc</last_name>
    <role>Study Chair</role>
    <affiliation>Faculdade de Medicina de Valença</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andréia A Azevedo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otosul -Otorrinolaringologia Sul-Fluminense</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OTOSUL,Otorrinolaringologia Sul-Fluminense</name>
      <address>
        <city>Volta Redonda</city>
        <state>RJ</state>
        <zip>27255-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>March 6, 2008</last_update_submitted>
  <last_update_submitted_qc>March 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andréia Aparecida de Azevedo, M.D.</name_title>
    <organization>OTOSUL</organization>
  </responsible_party>
  <keyword>tinnitus</keyword>
  <keyword>piribedil</keyword>
  <keyword>acoustic otoemissions</keyword>
  <keyword>ECoG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piribedil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

